Differences between imitations and genuine products of the targeted drug sotoracib (AMG510)

Sotorasiib (AMG510) is a targeted drug for KRAS G12C mutant locally advanced or metastatic non-small cell lung cancer. The original drug Sotorasibu was originally developed by Amgen in the United States. It is an acrylamide-derived KRAS inhibitor, also known as AMG-510. The original drug is usually more expensive due to higher costs of research and development, clinical trials, etc. The price of the original version in Hong Kong may be around around RMB 80,000 in Europe The price of the original research version may be more than 40,000 RMB (the price may fluctuate due to the exchange rate); while the imitation product has a lower price because there is no relevant cost. The price of the Laos Lucius version may be more than 1,000 RMB, and the price of the Big Bear version may be more than 2,000 RMB (the price may fluctuate due to the exchange rate).